Joel Stephen Finkelstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Density | 68 | 2022 | 3433 | 5.400 |
Why?
|
| Osteoporosis | 38 | 2022 | 1566 | 3.390 |
Why?
|
| Menopause | 21 | 2023 | 1605 | 2.580 |
Why?
|
| Teriparatide | 11 | 2014 | 226 | 2.400 |
Why?
|
| Testosterone | 33 | 2020 | 2386 | 2.100 |
Why?
|
| Absorptiometry, Photon | 26 | 2022 | 1691 | 2.040 |
Why?
|
| Osteoporosis, Postmenopausal | 11 | 2016 | 385 | 1.900 |
Why?
|
| Cystic Fibrosis | 7 | 2022 | 1145 | 1.760 |
Why?
|
| Radius | 12 | 2021 | 413 | 1.750 |
Why?
|
| Goserelin | 6 | 2020 | 127 | 1.740 |
Why?
|
| Libido | 4 | 2020 | 119 | 1.680 |
Why?
|
| Estradiol | 23 | 2019 | 2013 | 1.650 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2023 | 400 | 1.540 |
Why?
|
| Bone Density Conservation Agents | 11 | 2022 | 767 | 1.470 |
Why?
|
| Fractures, Bone | 15 | 2022 | 1882 | 1.440 |
Why?
|
| Tibia | 7 | 2018 | 1045 | 1.250 |
Why?
|
| Bone and Bones | 11 | 2021 | 2565 | 1.130 |
Why?
|
| Body Composition | 13 | 2022 | 2416 | 1.130 |
Why?
|
| Fragile X Mental Retardation Protein | 2 | 2016 | 116 | 1.090 |
Why?
|
| Bone Diseases, Metabolic | 6 | 2022 | 412 | 1.080 |
Why?
|
| Androstenedione | 5 | 2002 | 131 | 1.020 |
Why?
|
| Leuprolide | 7 | 2017 | 312 | 1.020 |
Why?
|
| Gonadotropin-Releasing Hormone | 17 | 2017 | 1200 | 0.990 |
Why?
|
| Lumbar Vertebrae | 19 | 2022 | 1823 | 0.920 |
Why?
|
| Women's Health | 17 | 2022 | 1992 | 0.920 |
Why?
|
| Alendronate | 5 | 2010 | 169 | 0.910 |
Why?
|
| Bone Remodeling | 11 | 2018 | 577 | 0.870 |
Why?
|
| Menstrual Cycle | 5 | 2020 | 525 | 0.790 |
Why?
|
| Aminophenols | 1 | 2021 | 76 | 0.770 |
Why?
|
| Vitamin D | 9 | 2019 | 3177 | 0.740 |
Why?
|
| Muscle Strength | 2 | 2013 | 560 | 0.710 |
Why?
|
| Hypogonadism | 14 | 2016 | 772 | 0.700 |
Why?
|
| Anabolic Agents | 3 | 2010 | 247 | 0.680 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2019 | 1513 | 0.680 |
Why?
|
| Premenopause | 10 | 2022 | 1026 | 0.630 |
Why?
|
| Quinolones | 1 | 2021 | 390 | 0.620 |
Why?
|
| Parathyroid Hormone | 10 | 2012 | 1810 | 0.590 |
Why?
|
| Bone Resorption | 7 | 2013 | 738 | 0.580 |
Why?
|
| Eunuchism | 1 | 2016 | 19 | 0.570 |
Why?
|
| Climacteric | 4 | 2004 | 57 | 0.560 |
Why?
|
| Perimenopause | 4 | 2017 | 138 | 0.550 |
Why?
|
| Reproduction | 2 | 2020 | 654 | 0.540 |
Why?
|
| Vitamin D Deficiency | 7 | 2019 | 1340 | 0.530 |
Why?
|
| Femur Neck | 9 | 2022 | 308 | 0.530 |
Why?
|
| Ergocalciferols | 2 | 2015 | 110 | 0.520 |
Why?
|
| Prescriptions | 2 | 2021 | 360 | 0.510 |
Why?
|
| Aromatase Inhibitors | 6 | 2019 | 493 | 0.510 |
Why?
|
| Middle Aged | 95 | 2022 | 212292 | 0.510 |
Why?
|
| Postmenopause | 8 | 2021 | 2440 | 0.500 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 168 | 0.470 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2013 | 25 | 0.470 |
Why?
|
| Fibroblast Growth Factors | 2 | 2012 | 885 | 0.460 |
Why?
|
| Hormones | 7 | 2017 | 868 | 0.460 |
Why?
|
| Adult | 94 | 2022 | 211615 | 0.460 |
Why?
|
| Nafarelin | 4 | 1999 | 27 | 0.430 |
Why?
|
| Spinal Neoplasms | 6 | 2015 | 758 | 0.430 |
Why?
|
| Female | 107 | 2023 | 375449 | 0.410 |
Why?
|
| Bone Cements | 4 | 2006 | 324 | 0.410 |
Why?
|
| Adipose Tissue | 4 | 2022 | 3264 | 0.410 |
Why?
|
| Obesity, Morbid | 3 | 2018 | 1096 | 0.400 |
Why?
|
| Puberty, Delayed | 3 | 1999 | 111 | 0.400 |
Why?
|
| Adiposity | 2 | 2020 | 1785 | 0.400 |
Why?
|
| Menstruation | 5 | 2020 | 289 | 0.390 |
Why?
|
| Spinal Fractures | 7 | 2011 | 679 | 0.390 |
Why?
|
| Gastric Bypass | 2 | 2018 | 745 | 0.390 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 1535 | 0.390 |
Why?
|
| Humans | 160 | 2023 | 725187 | 0.390 |
Why?
|
| Gonadotropins | 6 | 1991 | 241 | 0.390 |
Why?
|
| Fractures, Spontaneous | 9 | 2011 | 227 | 0.380 |
Why?
|
| Infertility, Female | 1 | 2016 | 778 | 0.380 |
Why?
|
| Polymethyl Methacrylate | 3 | 2006 | 141 | 0.380 |
Why?
|
| Drug Utilization | 2 | 2016 | 1182 | 0.370 |
Why?
|
| Follicle Stimulating Hormone | 16 | 2019 | 744 | 0.370 |
Why?
|
| Proton Pump Inhibitors | 1 | 2015 | 503 | 0.370 |
Why?
|
| Spinal Cord Compression | 2 | 2015 | 237 | 0.370 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 2001 | 0.370 |
Why?
|
| Prostatic Neoplasms | 11 | 2011 | 10884 | 0.360 |
Why?
|
| Longitudinal Studies | 23 | 2020 | 13698 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2018 | 19908 | 0.340 |
Why?
|
| Prescription Drugs | 1 | 2016 | 578 | 0.340 |
Why?
|
| Cohort Studies | 29 | 2021 | 39918 | 0.340 |
Why?
|
| Male | 95 | 2022 | 347096 | 0.340 |
Why?
|
| Phosphates | 3 | 2012 | 793 | 0.340 |
Why?
|
| Estrogens | 5 | 2017 | 1559 | 0.340 |
Why?
|
| Peptide Fragments | 3 | 2019 | 5037 | 0.320 |
Why?
|
| Orthopedic Procedures | 3 | 2008 | 1264 | 0.320 |
Why?
|
| Osteocalcin | 7 | 2012 | 271 | 0.310 |
Why?
|
| Decompression, Surgical | 2 | 2014 | 593 | 0.310 |
Why?
|
| Injections, Subcutaneous | 4 | 2020 | 674 | 0.300 |
Why?
|
| Gonadal Steroid Hormones | 9 | 2014 | 703 | 0.300 |
Why?
|
| Androgens | 5 | 2019 | 1248 | 0.300 |
Why?
|
| Spinal Osteophytosis | 1 | 2006 | 28 | 0.290 |
Why?
|
| Spine | 9 | 2018 | 1108 | 0.290 |
Why?
|
| Spinal Canal | 1 | 2006 | 38 | 0.290 |
Why?
|
| Osteoporotic Fractures | 2 | 2022 | 383 | 0.290 |
Why?
|
| Dietary Supplements | 6 | 2019 | 3225 | 0.290 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2017 | 129 | 0.280 |
Why?
|
| Health Behavior | 2 | 2016 | 2578 | 0.280 |
Why?
|
| Spinal Fusion | 3 | 2014 | 1211 | 0.270 |
Why?
|
| Nitriles | 3 | 2005 | 940 | 0.270 |
Why?
|
| Trinucleotide Repeats | 2 | 2016 | 261 | 0.270 |
Why?
|
| Laminectomy | 1 | 2006 | 231 | 0.270 |
Why?
|
| Aging | 5 | 2020 | 8530 | 0.260 |
Why?
|
| Aged | 49 | 2021 | 161486 | 0.260 |
Why?
|
| Pain, Intractable | 1 | 2006 | 130 | 0.260 |
Why?
|
| Patient Compliance | 6 | 2017 | 2682 | 0.260 |
Why?
|
| Bone Development | 5 | 2005 | 484 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2020 | 10971 | 0.250 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 882 | 0.250 |
Why?
|
| Ovary | 3 | 2023 | 997 | 0.250 |
Why?
|
| Vitamins | 2 | 2012 | 1560 | 0.250 |
Why?
|
| Follow-Up Studies | 15 | 2022 | 38748 | 0.240 |
Why?
|
| Diphosphonates | 4 | 2007 | 617 | 0.240 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 2769 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2022 | 21591 | 0.240 |
Why?
|
| Spinal Diseases | 2 | 2008 | 536 | 0.240 |
Why?
|
| Triazoles | 3 | 2014 | 909 | 0.230 |
Why?
|
| Insulin Resistance | 5 | 2022 | 3871 | 0.230 |
Why?
|
| Epitestosterone | 1 | 2002 | 3 | 0.230 |
Why?
|
| United States | 22 | 2021 | 68403 | 0.220 |
Why?
|
| Endometriosis | 3 | 1999 | 810 | 0.210 |
Why?
|
| Administration, Cutaneous | 2 | 2020 | 693 | 0.210 |
Why?
|
| Aged, 80 and over | 24 | 2020 | 57656 | 0.210 |
Why?
|
| Overweight | 1 | 2013 | 2285 | 0.210 |
Why?
|
| Collagen Type I | 6 | 2014 | 575 | 0.200 |
Why?
|
| Estranes | 1 | 2000 | 2 | 0.200 |
Why?
|
| Anilides | 1 | 2004 | 412 | 0.200 |
Why?
|
| Nandrolone | 1 | 2000 | 17 | 0.200 |
Why?
|
| Calcium | 5 | 2006 | 5758 | 0.200 |
Why?
|
| Penile Erection | 1 | 2020 | 94 | 0.190 |
Why?
|
| Bone Neoplasms | 5 | 2017 | 2512 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 4 | 2012 | 7254 | 0.180 |
Why?
|
| Prospective Studies | 12 | 2022 | 51869 | 0.180 |
Why?
|
| Cervical Vertebrae | 1 | 2006 | 953 | 0.180 |
Why?
|
| Young Adult | 12 | 2022 | 55781 | 0.180 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 116 | 0.180 |
Why?
|
| Drug Contamination | 1 | 2000 | 146 | 0.180 |
Why?
|
| Luteinizing Hormone | 13 | 2017 | 870 | 0.180 |
Why?
|
| Gels | 1 | 2020 | 429 | 0.170 |
Why?
|
| Body Fat Distribution | 1 | 2020 | 241 | 0.170 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 975 | 0.170 |
Why?
|
| Treatment Outcome | 20 | 2020 | 61761 | 0.170 |
Why?
|
| Body Mass Index | 9 | 2022 | 12523 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6460 | 0.160 |
Why?
|
| Mass Screening | 2 | 2012 | 5197 | 0.160 |
Why?
|
| Hip | 2 | 2021 | 250 | 0.160 |
Why?
|
| Body Weight | 4 | 2019 | 4657 | 0.160 |
Why?
|
| Reference Values | 5 | 2016 | 4999 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2012 | 6163 | 0.160 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2021 | 420 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 681 | 0.150 |
Why?
|
| Prediabetic State | 1 | 2022 | 476 | 0.150 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 958 | 0.150 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2014 | 1144 | 0.150 |
Why?
|
| Orthopedics | 3 | 2022 | 877 | 0.150 |
Why?
|
| Estrone | 4 | 2017 | 240 | 0.140 |
Why?
|
| Blood Chemical Analysis | 2 | 2014 | 442 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 1804 | 0.140 |
Why?
|
| Galactose | 1 | 2017 | 303 | 0.140 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2015 | 75 | 0.140 |
Why?
|
| Immunoassay | 2 | 2012 | 751 | 0.140 |
Why?
|
| Receptors, Histamine H2 | 1 | 2015 | 18 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 3360 | 0.130 |
Why?
|
| Time Factors | 11 | 2015 | 40186 | 0.130 |
Why?
|
| Femur | 3 | 2012 | 1284 | 0.130 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 3 | 1990 | 42 | 0.130 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 24031 | 0.130 |
Why?
|
| Calcitriol | 3 | 2006 | 304 | 0.130 |
Why?
|
| Collagen | 4 | 2013 | 2668 | 0.130 |
Why?
|
| Eating | 1 | 2022 | 1524 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 2 | 2015 | 740 | 0.130 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 9 | 0.130 |
Why?
|
| Tibial Fractures | 1 | 2017 | 247 | 0.120 |
Why?
|
| Androgen Antagonists | 3 | 2011 | 1328 | 0.120 |
Why?
|
| Urinalysis | 3 | 2002 | 357 | 0.120 |
Why?
|
| Glycosylation | 1 | 2017 | 1109 | 0.120 |
Why?
|
| Osteogenesis | 3 | 2014 | 1295 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2014 | 12249 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2019 | 946 | 0.110 |
Why?
|
| Propensity Score | 2 | 2019 | 1755 | 0.110 |
Why?
|
| Patient Education as Topic | 3 | 2008 | 2284 | 0.110 |
Why?
|
| Spondylolisthesis | 1 | 2014 | 159 | 0.110 |
Why?
|
| Motor Activity | 3 | 2014 | 2712 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2009 | 1924 | 0.110 |
Why?
|
| Sex Hormone-Binding Globulin | 6 | 2019 | 547 | 0.110 |
Why?
|
| Peptides | 6 | 2014 | 4390 | 0.110 |
Why?
|
| Adolescent | 15 | 2022 | 84401 | 0.110 |
Why?
|
| Obesity | 2 | 2019 | 12419 | 0.110 |
Why?
|
| Risk Factors | 13 | 2019 | 71009 | 0.100 |
Why?
|
| Alkaline Phosphatase | 3 | 2003 | 863 | 0.100 |
Why?
|
| Administration, Oral | 4 | 2002 | 3909 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2021 | 2537 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 428 | 0.100 |
Why?
|
| Hypercalcemia | 1 | 2014 | 405 | 0.100 |
Why?
|
| Finite Element Analysis | 1 | 2013 | 427 | 0.100 |
Why?
|
| Weight-Bearing | 1 | 2013 | 495 | 0.100 |
Why?
|
| Sex Factors | 6 | 2017 | 10382 | 0.100 |
Why?
|
| Fertility | 1 | 2016 | 756 | 0.100 |
Why?
|
| Japan | 2 | 2013 | 1344 | 0.100 |
Why?
|
| Prognosis | 4 | 2020 | 28737 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2017 | 1029 | 0.090 |
Why?
|
| Diet | 2 | 2006 | 7797 | 0.090 |
Why?
|
| Fractures, Compression | 1 | 2011 | 129 | 0.090 |
Why?
|
| Pituitary Gland | 4 | 1989 | 666 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1214 | 0.090 |
Why?
|
| Age Factors | 7 | 2015 | 18339 | 0.090 |
Why?
|
| Logistic Models | 5 | 2019 | 13358 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2016 | 3593 | 0.090 |
Why?
|
| Risk | 3 | 2019 | 9700 | 0.090 |
Why?
|
| Blood Glucose | 4 | 2022 | 6217 | 0.090 |
Why?
|
| China | 2 | 2013 | 2199 | 0.090 |
Why?
|
| Procollagen | 2 | 2006 | 188 | 0.090 |
Why?
|
| Substance Abuse Detection | 2 | 2002 | 287 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1479 | 0.080 |
Why?
|
| Embalming | 1 | 1988 | 13 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2008 | 3892 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 9839 | 0.080 |
Why?
|
| Pelvic Bones | 2 | 2018 | 265 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2019 | 23185 | 0.080 |
Why?
|
| Boston | 4 | 2015 | 9288 | 0.080 |
Why?
|
| Gynecomastia | 1 | 1988 | 88 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 11413 | 0.080 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 473 | 0.080 |
Why?
|
| Retreatment | 1 | 2009 | 607 | 0.080 |
Why?
|
| Versicans | 1 | 2007 | 32 | 0.080 |
Why?
|
| Anthropometry | 2 | 2002 | 1357 | 0.080 |
Why?
|
| Linear Models | 3 | 2014 | 5937 | 0.080 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 2750 | 0.080 |
Why?
|
| Pharmacoepidemiology | 2 | 2019 | 322 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2002 | 1661 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2692 | 0.070 |
Why?
|
| Weight Gain | 2 | 2019 | 2238 | 0.070 |
Why?
|
| Quality of Life | 4 | 2006 | 12111 | 0.070 |
Why?
|
| Seasons | 1 | 2012 | 1470 | 0.070 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1476 | 0.070 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2008 | 149 | 0.070 |
Why?
|
| Endocrinology | 1 | 2012 | 415 | 0.070 |
Why?
|
| Body Constitution | 2 | 2004 | 276 | 0.070 |
Why?
|
| Exercise | 2 | 2022 | 5487 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2017 | 2540 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 7670 | 0.070 |
Why?
|
| Physicians, Family | 1 | 2007 | 348 | 0.070 |
Why?
|
| Aromatase | 1 | 2005 | 148 | 0.070 |
Why?
|
| Canada | 3 | 2015 | 1989 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2009 | 415 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3511 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2010 | 1448 | 0.070 |
Why?
|
| Palliative Care | 4 | 2017 | 3355 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4497 | 0.060 |
Why?
|
| Anorexia Nervosa | 1 | 2014 | 1271 | 0.060 |
Why?
|
| Osteoprotegerin | 1 | 2005 | 178 | 0.060 |
Why?
|
| Length of Stay | 2 | 2015 | 6234 | 0.060 |
Why?
|
| Pennsylvania | 4 | 2008 | 611 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17354 | 0.060 |
Why?
|
| Tosyl Compounds | 1 | 2004 | 114 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 3 | 2011 | 2354 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2021 | 908 | 0.060 |
Why?
|
| Weight Loss | 1 | 2015 | 2521 | 0.060 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 2472 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3877 | 0.060 |
Why?
|
| Pain | 3 | 2016 | 4830 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2003 | 107 | 0.060 |
Why?
|
| Pregnanediol | 2 | 2017 | 17 | 0.060 |
Why?
|
| Androsterone | 2 | 2001 | 14 | 0.060 |
Why?
|
| Etiocholanolone | 2 | 2001 | 7 | 0.060 |
Why?
|
| Control Groups | 1 | 2002 | 106 | 0.060 |
Why?
|
| Patient Selection | 3 | 2015 | 4200 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 604 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2014 | 2909 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2006 | 1204 | 0.050 |
Why?
|
| Medicare | 2 | 2012 | 6252 | 0.050 |
Why?
|
| Corpus Luteum | 2 | 2017 | 89 | 0.050 |
Why?
|
| Adiponectin | 1 | 2008 | 1087 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2016 | 3411 | 0.050 |
Why?
|
| Glucuronides | 1 | 2001 | 21 | 0.050 |
Why?
|
| Calcifediol | 2 | 2015 | 170 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 13576 | 0.050 |
Why?
|
| Syndrome | 1 | 2008 | 3223 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 3296 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2012 | 2240 | 0.050 |
Why?
|
| Hip Joint | 3 | 2014 | 979 | 0.050 |
Why?
|
| Drug Administration Schedule | 5 | 2007 | 4938 | 0.050 |
Why?
|
| Propylamines | 3 | 1966 | 164 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2007 | 2260 | 0.050 |
Why?
|
| Dihydrotestosterone | 1 | 2001 | 192 | 0.050 |
Why?
|
| HIV Wasting Syndrome | 1 | 2001 | 99 | 0.050 |
Why?
|
| Sodium | 1 | 2006 | 1594 | 0.050 |
Why?
|
| Safety | 1 | 2006 | 1189 | 0.050 |
Why?
|
| Monoamine Oxidase Inhibitors | 3 | 1966 | 156 | 0.050 |
Why?
|
| Life Style | 2 | 2002 | 3780 | 0.050 |
Why?
|
| Imidazoles | 1 | 2007 | 1226 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2008 | 1791 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2013 | 3702 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1637 | 0.050 |
Why?
|
| Insulin | 1 | 2015 | 6562 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 858 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2023 | 662 | 0.050 |
Why?
|
| New England | 1 | 2003 | 987 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3621 | 0.050 |
Why?
|
| Family Practice | 1 | 2003 | 517 | 0.050 |
Why?
|
| Calcium Gluconate | 1 | 1999 | 23 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 1988 | 1466 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 15442 | 0.040 |
Why?
|
| Pirenzepine | 1 | 1999 | 115 | 0.040 |
Why?
|
| Blood Pressure | 3 | 2019 | 8475 | 0.040 |
Why?
|
| Phenotype | 2 | 2016 | 16272 | 0.040 |
Why?
|
| Inpatients | 2 | 2022 | 2395 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2004 | 605 | 0.040 |
Why?
|
| Joint Instability | 1 | 2006 | 767 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2006 | 2728 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 8918 | 0.040 |
Why?
|
| Health Maintenance Organizations | 1 | 2001 | 653 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1800 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2001 | 526 | 0.040 |
Why?
|
| Lipids | 2 | 2008 | 3298 | 0.040 |
Why?
|
| Incidence | 2 | 2015 | 20750 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2002 | 1148 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2006 | 919 | 0.040 |
Why?
|
| Feedback | 2 | 1991 | 765 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 1978 | 113 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2049 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2009 | 2015 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2022 | 1170 | 0.040 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3416 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1978 | 163 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2017 | 176 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2015 | 11883 | 0.040 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1997 | 89 | 0.040 |
Why?
|
| Sports | 1 | 2003 | 661 | 0.040 |
Why?
|
| Sodium Oxybate | 1 | 1997 | 31 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2005 | 2297 | 0.040 |
Why?
|
| Fertility Agents, Female | 1 | 2017 | 98 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2023 | 916 | 0.040 |
Why?
|
| Accidental Falls | 2 | 2019 | 1028 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 1533 | 0.040 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1999 | 229 | 0.040 |
Why?
|
| Ontario | 1 | 2017 | 368 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 3689 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2022 | 1495 | 0.040 |
Why?
|
| Sunlight | 1 | 1998 | 329 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 586 | 0.040 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2015 | 39 | 0.030 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2017 | 265 | 0.030 |
Why?
|
| Retrospective Studies | 8 | 2021 | 74206 | 0.030 |
Why?
|
| Iproniazid | 2 | 1966 | 9 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2014 | 47 | 0.030 |
Why?
|
| Light | 2 | 1978 | 1397 | 0.030 |
Why?
|
| Amino Acids | 1 | 2001 | 1724 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1989 | 1031 | 0.030 |
Why?
|
| Radionuclide Imaging | 2 | 1989 | 2016 | 0.030 |
Why?
|
| Gonads | 1 | 2014 | 109 | 0.030 |
Why?
|
| Child | 4 | 2021 | 75163 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 3822 | 0.030 |
Why?
|
| Porosity | 1 | 2014 | 359 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 3615 | 0.030 |
Why?
|
| Osteolysis | 2 | 2007 | 264 | 0.030 |
Why?
|
| Health Services Research | 1 | 2001 | 1830 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 6355 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2005 | 238 | 0.030 |
Why?
|
| Thyrotropin | 2 | 2003 | 818 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2000 | 2222 | 0.030 |
Why?
|
| Self Efficacy | 2 | 2008 | 607 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 2904 | 0.030 |
Why?
|
| Radioimmunoassay | 3 | 1989 | 936 | 0.030 |
Why?
|
| Testolactone | 1 | 1991 | 7 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 1999 | 1354 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2014 | 296 | 0.030 |
Why?
|
| Calibration | 1 | 1994 | 817 | 0.030 |
Why?
|
| Glucocorticoids | 2 | 2008 | 2085 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2004 | 2352 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 1616 | 0.030 |
Why?
|
| Human Growth Hormone | 1 | 1996 | 687 | 0.030 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 1990 | 95 | 0.020 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 14974 | 0.020 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 20448 | 0.020 |
Why?
|
| Women | 1 | 2012 | 227 | 0.020 |
Why?
|
| Medical Records | 1 | 1996 | 1416 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3172 | 0.020 |
Why?
|
| Iodobenzoates | 1 | 1989 | 11 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 2021 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 1991 | 230 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1998 | 6398 | 0.020 |
Why?
|
| Radiography | 2 | 2011 | 6935 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 1989 | 124 | 0.020 |
Why?
|
| Fracture Healing | 1 | 2011 | 410 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2918 | 0.020 |
Why?
|
| Prevalence | 2 | 2012 | 14992 | 0.020 |
Why?
|
| Testis | 2 | 1989 | 804 | 0.020 |
Why?
|
| Periodicity | 4 | 1990 | 372 | 0.020 |
Why?
|
| Algorithms | 1 | 2009 | 13765 | 0.020 |
Why?
|
| Viscera | 1 | 1989 | 141 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1587 | 0.020 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1988 | 73 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2008 | 177 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1988 | 160 | 0.020 |
Why?
|
| Sleep | 2 | 2021 | 4406 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2007 | 65 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 2008 | 243 | 0.020 |
Why?
|
| Isocarboxazid | 1 | 1966 | 7 | 0.020 |
Why?
|
| Tranylcypromine | 1 | 1966 | 29 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4896 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2003 | 4488 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 1999 | 3012 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 1442 | 0.020 |
Why?
|
| Body Height | 1 | 2012 | 1575 | 0.020 |
Why?
|
| Calcitonin | 1 | 2007 | 337 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 167 | 0.020 |
Why?
|
| Sexual Maturation | 1 | 1986 | 259 | 0.020 |
Why?
|
| Chickens | 1 | 2007 | 866 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 6432 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 2443 | 0.020 |
Why?
|
| Densitometry | 1 | 2004 | 155 | 0.020 |
Why?
|
| Hand | 1 | 2009 | 870 | 0.010 |
Why?
|
| Extremities | 1 | 1989 | 857 | 0.010 |
Why?
|
| Polypharmacy | 1 | 2005 | 283 | 0.010 |
Why?
|
| Angiography | 1 |